Gain essential feedback from quality assessors
MHRA and Swissmedic presenting.
Including 20 industry experts from Pfizer, H.Lundbeck, Novo Nordisk, Merck, AstraZeneca, Sanofi Aventis, Novartis, Eisai and others
- 7x in-depth industry case studies
- 7x subject sessions
- 20x speakers
- 1x whole day on QbD
- 1x new evening seminar
7+ hours of networking with industry leaders from large, medium and small sized pharma and generics companies
90% of NCEs and 40% of existing drugs are poorly soluble or lipophilic. A key focus of this conference is on technologies and strategies that are available to overcome this industry challenge.
Attend the conference and find out how amorphous materials, co-crystals, nano & micro and self-emulsifying formulations can help.
Frank Thielmann, Operational Lead Inhalation, Novartis Pharma, Switzerland
Sushil K. Srivastava, Director, Chemical Development, Bristol-Myers Squibb, USA
Mette Bryder, Head of Biologics & Pharmaceutical Science Department, Lundbeck A/S, Denmark
Martin Schubert, Head of Chemical Pharmaceutical Development, UCB Pharma, Belgium
Sune Klint Andersen, Principal Scientist, Novo Nordisk A/S, Denmark
David Elder, Director, GlaxoSmithKline, UK
Research and development departments are trying hard to reduce cost and development times. Effective and efficient formulation development is one way that teams across industry are achieving this. Find out how industry peers are speeding up formulation development and learn from their best practice.
Meet, network and make new contacts with the following professionals…
Heads, Managers, Senior Scientists, Principle Scientists, Scientists and Researchers from:
Delegates attend from large, medium and small pharma, biotech and generics companies
Why should you attend? Take a look at the conference highlights to find out.